Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 18, 2020
Daily News
February 18, 2020
- Authorized Generics for Memary, Celecox among Approval List towards June Listing
February 18, 2020
- Takeda’s Entyvio SC Form Hits Main Goal in PIII Crohn’s Disease Study
February 18, 2020
- MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
February 18, 2020
- HIV Med Pifeltro Now Available in Japan: MSD
February 18, 2020
- Chugai, Sanofi Wind Up License Deal for Apleway; Kowa to Get MA
February 18, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…